NCT03109847View on ClinicalTrials.gov

Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 5, 2017

Primary Completion Date

December 29, 2020

Study Completion Date

December 7, 2022

Conditions
Thyroid
Interventions
DRUG

Metformin Hydrochloride

Given Orally

OTHER

Radioactive Iodine

Undergo radioactive iodine treatment

OTHER

Placebo

Given orally

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03109847 - Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter